Search - tctmd.com

Displaying 201 - 220 of 1046

Sort: Relevancy | Date

Presentation TCT 2021

Short-term Priorities: Optimal Intervention for the Patient With Longer Life Expectancy

Presenter: Amar Krishnaswamy

November 05, 2021

Presentation TCT 2021

The Journey in Clinical Context (Case Presentation)

Presenter: Itsik Ben-Dor

November 05, 2021

News Conference News TCT 2021

Disrupt CAD III Shows Sustained Benefit for Lithotripsy at 1 Year

L.A. McKeown

November 05, 2021

Presentation TCT 2021

Special (Device/Drug) Approaches to Infarct Size Reduction

Presenter: Giovanni Luigi De Maria

November 05, 2021

Presentation TCT 2021

Drug Therapy for No Re-Flow

Presenter: Somjot Brar

November 05, 2021

Presentation TCT 2021

How Do We Identify Patients With Microvascular Dysfunction and Define Their Risk (Pressure Wire, Angiography, MRI)?

Presenter: Adrian Banning

November 05, 2021

Presentation TCT 2021

Latest Evidence in the SPYRAL-HTN Clinical Program

Presenter: NULL

November 05, 2021

Presentation TCT 2021

Digital Health Apps in Cardiovascular Device Trials, a Clinician's Perspective

Presenter: Mintu Turakhia

November 05, 2021

Presentation TCT 2021

Management of High Thrombus Burden: What Is the Role of Aspiration/ Intravenous Antipletelets/Intracoronary Lytic?

Presenter: J. Dawn Abbott

November 05, 2021

Presentation TCT 2021

Options for Immediate vs Staging Multivessel Revascularization in STEMI

Presenter: Timothy Henry

November 05, 2021

Presentation TCT 2021

Optimising Pharmacoinvasive Therapies for STEMI Patients Prior to PCI

Presenter: Robert Welsh

November 05, 2021

News Conference News TCT 2021

PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term

Todd Neale

November 05, 2021

Presentation TCT 2021

MASTER-DAPT: A Randomized Trial of Abbreviated Antiplatelet Therapy - Outcomes in High Bleeding Risk Patients With High Thrombotic and Ischemic Risk

Presenter: Pieter Smits

November 05, 2021

Presentation TCT 2021

PRAGUE-17: Three-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure Versus Direct Acting Oral Anticoagulation in Patients With Atrial Fibrillation

Presenter: Pavel Osmancik

November 05, 2021

Presentation TCT 2021

AMULET IDE: One-Year Device Closure From a Randomized Trial of Amulet Versus Watchman for Left Atrial Appendage Occlusion

Presenter: Dhanunjaya Lakkireddy

November 05, 2021

Presentation TCT 2021

CHOICE-CLOSURE: A Randomized Trial of Plug-Based Versus Suture-Based Large-Bore Vascular Closure

Presenter: Mohamed Abdel-Wahab

November 05, 2021

News Conference News TCT 2021

More Complications With Plug Closure After TAVI: CHOICE-CLOSURE

Michael O'Riordan

November 05, 2021

Presentation TCT 2021

A Novel Sirolimus-Eluting Iron-Based Bioresorbable Scaffold Implantation in Single De Novo Coronary Lesions: Two-Year Clinical and Imaging Outcomes from the First in Man Study (IBS-FIM)

Presenter: Runlin Gao

November 05, 2021

Presentation TCT 2021

PARTNER 3: Two-Year Economic Outcomes From a Randomized Trial of TAVR vs. SAVR in Patients at Low Surgical Risk

Presenter: David Cohen

November 05, 2021

News Conference News TCT 2021

TAVI Edges Out Surgery in 2-Year Costs for Low-risk Patients: PARTNER 3

Yael L. Maxwell

November 05, 2021

Advertisement

Short-term Priorities: Optimal Intervention for the Patient With Longer Life Expectancy

The Journey in Clinical Context (Case Presentation)

Disrupt CAD III Shows Sustained Benefit for Lithotripsy at 1 Year

Special (Device/Drug) Approaches to Infarct Size Reduction

Drug Therapy for No Re-Flow

How Do We Identify Patients With Microvascular Dysfunction and Define Their Risk (Pressure Wire, Angiography, MRI)?

Latest Evidence in the SPYRAL-HTN Clinical Program

Digital Health Apps in Cardiovascular Device Trials, a Clinician's Perspective

Management of High Thrombus Burden: What Is the Role of Aspiration/ Intravenous Antipletelets/Intracoronary Lytic?

Options for Immediate vs Staging Multivessel Revascularization in STEMI

Optimising Pharmacoinvasive Therapies for STEMI Patients Prior to PCI

PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term

MASTER-DAPT: A Randomized Trial of Abbreviated Antiplatelet Therapy - Outcomes in High Bleeding Risk Patients With High Thrombotic and Ischemic Risk

PRAGUE-17: Three-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure Versus Direct Acting Oral Anticoagulation in Patients With Atrial Fibrillation

AMULET IDE: One-Year Device Closure From a Randomized Trial of Amulet Versus Watchman for Left Atrial Appendage Occlusion

CHOICE-CLOSURE: A Randomized Trial of Plug-Based Versus Suture-Based Large-Bore Vascular Closure

More Complications With Plug Closure After TAVI: CHOICE-CLOSURE

A Novel Sirolimus-Eluting Iron-Based Bioresorbable Scaffold Implantation in Single De Novo Coronary Lesions: Two-Year Clinical and Imaging Outcomes from the First in Man Study (IBS-FIM)

PARTNER 3: Two-Year Economic Outcomes From a Randomized Trial of TAVR vs. SAVR in Patients at Low Surgical Risk

TAVI Edges Out Surgery in 2-Year Costs for Low-risk Patients: PARTNER 3

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content